As a result of this damage, various diseases may occur
As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment
Serum B12 reference ranges vary between laboratories, but generally, levels below 148 pmol/L are considered deficient, whilst levels between 148258 pmol/L are regarded as borderline and may warrant further investigation or a trial of treatment, particularly if symptoms are present
We design highly compatible disulfide bond linkers for various antibody types (monoclonal antibodies, bispecific antibodies, antibody fragments) to ensure conjugation efficiency and antibody activity
Templeman C, Marshall SF, Clarke CA, DeLellis HK, Largent J, Neuhausen S, et al
X.ChengX